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Effects and Prevention of Chronic NSAID Use on the Stomach
Abstract
Purpose: As our population continues to age, the prevalence of nonspecific nonsteroidal anti-inflammatory
drugs (nsNSAID) and cyclooxygenase-2 (COX-2) inhibitor use increases. Each year approximately 3,200 to
>16,500 deaths are attributed to gastrointestinal (GI) toxicity secondary to NSAID use. With the growing
concern of the damage these medications can do to the gastric mucosa, the prevention of GI injury is an
important clinical issue. The purpose of this review was to determine the current recommendations for
prescribing nsNSAID and COX-2 inhibitor drugs in relation to minimizing GI injury.
Methods: An extensive literature review in English was performed searching for articles over the past 10 years
using terms related to NSAIDS and GI complications Articles were rejected if the study was not a randomized
controlled trial or retrospective cohort trial; included exclusively children; lasted less than 21 days; or did not
measure review outcomes.
Results: NSAID vs COX-2 – Three randomized controlled trials demonstrated the same result: COX-2
selective inhibitors were associated with less significant GI effects than nsNSAIDs alone. However, two out of
the three tests came under scrutiny and the results were thought to be biased and not completely reported.
COX-2 vs. NSAID plus PPI - Studies found that a COX-2 inhibitor was as effective as an NSAID plus a PPI
with respect to the prevention of recurrent bleeding. However, the studies agreed that even though the two
methods were as effective, the risk of recurrent bleeding with either treatment was high, suggesting that
neither regimen could completely protect patients at high risk from recurrent ulcer complications. COX-2 vs.
COX-2 plus PPI – Studies determined that combination treatment was more effective then COX-2 inhibitors
alone, for the prevention of ulcer bleeding in patients at high risk. The study defined high risk as patients with
a previous history of ulcer bleeding. A limitation noted in a study was the inability to assess the best possible
management for patients with high cardiovascular risk and therefore the role of concomitant aspirin in
relation to the efficacy of COX-2 inhibitors. NSADI plus PPI vs. COX-s plus PPI – The VENUS and PLUTO
studies were conducted at the same time and both concluded that significant reductions in ulcer development
were observed for users of both nsNSAIDs and COX-2 inhibitors in combination with a PPI. However, the
trial sizes were of significant difference and the percentage of patients in the VENUS study that had a history
of ulcer as their sole risk factor was significantly lower than in the PLUTO group.
Conclusion: Many of early studies on COX-2 inhibitors were done by the drug companies themselves, and
therefore contained biased information. In the recent years, viable data has emerged to help us make decisions
about the proper care for our chronic NSAID-use patients. Upper GI injury while taking aspirin or NSAID’s is
typically related to risk factors, dosages and duration spent taking the drug. Therefore, the smaller the dose
and the less time spent on the drug will help decrease the risk of developing some sort of GI injury. In the
instance where a patient will need to take chronic NSAID therapy, it is recommended a patient with no
cardiovascular risks (not taking aspirin) and with no or low risk of GI factors should take an nsNSAID. If a
patient with no cardiovascular risks has GI risks then it is recommended they take either a COX2 or an
nsNSAID with a PPI. Patients with cardiovascular risks and no GI risk should take nsNSAIDs with a PPI only
if GI risks warrant it. A patient with both cardiovascular and GI risks should take a nsNSAID with a PPI.
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Abstract   
Purpose:  As our population continues to age, the prevalence of nonspecific nonsteroidal anti-
inflammatory drugs (nsNSAID) and cyclooxygenase-2 (COX-2) inhibitor use increases.  Each 
year approximately 3,200 to >16,500 deaths are attributed to gastrointestinal (GI) toxicity 
secondary to NSAID use.  With the growing concern of the damage these medications can do to 
the gastric mucosa, the prevention of GI injury is an important clinical issue.  The purpose of this 
review was to determine the current recommendations for prescribing nsNSAID and COX-2 
inhibitor drugs in relation to minimizing GI injury.   Methods:  An extensive literature review in 
English was performed searching for articles over the past 10 years using terms related to 
NSAIDS and GI complications  Articles were rejected if the study was not a randomized 
controlled trial or retrospective cohort trial; included exclusively children; lasted less than 21 
days; or did not measure review outcomes. Results:  NSAID vs COX-2 – Three randomized 
controlled trials demonstrated the same result:  COX-2 selective inhibitors were associated with 
less significant GI effects than nsNSAIDs alone.  However, two out of the three tests came under 
scrutiny and the results were thought to be biased and not completely reported.  COX-2 vs. 
NSAID plus PPI -  Studies found that a COX-2 inhibitor was as effective as an NSAID plus a 
PPI with respect to the prevention of recurrent bleeding.  However, the studies agreed that even 
though the two methods were as effective, the risk of recurrent bleeding with either treatment 
was high, suggesting that neither regimen could completely protect patients at high risk from 
recurrent ulcer complications. COX-2 vs. COX-2 plus PPI – Studies determined that 
combination treatment was more effective then COX-2 inhibitors alone, for the prevention of 
ulcer bleeding in patients at high risk.  The study defined high risk as patients with a previous 
history of ulcer bleeding.  A limitation noted in a study was the inability to assess the best 
possible management for patients with high cardiovascular risk and therefore the role of 
concomitant aspirin in relation to the efficacy of COX-2 inhibitors.  NSADI plus PPI vs. COX-s 
plus PPI – The VENUS and PLUTO studies were conducted at the same time and both 
concluded that significant reductions in ulcer development were observed for users of both 
nsNSAIDs and COX-2 inhibitors in combination with a PPI.  However, the trial sizes were of 
significant difference and the percentage of patients in the VENUS study that had a history of 
ulcer as their sole risk factor was significantly lower than in the PLUTO group.  Conclusion:  
Many of early studies on COX-2 inhibitors were done by the drug companies themselves, and 
therefore contained biased information.  In the recent years, viable data has emerged to help us 
make decisions about the proper care for our chronic NSAID-use patients.  Upper GI injury 
while taking aspirin or NSAID’s is typically related to risk factors, dosages and duration spent 
taking the drug.  Therefore, the smaller the dose and the less time spent on the drug will help 
decrease the risk of developing some sort of GI injury.  In the instance where a patient will need 
to take chronic NSAID therapy, it is recommended a patient with no cardiovascular risks (not 
taking aspirin) and with no or low risk of GI factors should take an nsNSAID.  If a patient with 
no cardiovascular risks has GI risks then it is recommended they take either a COX2 or an 
nsNSAID with a PPI.  Patients with cardiovascular risks and no GI risk should take nsNSAIDs 
with a PPI only if GI risks warrant it.  A patient with both cardiovascular and GI risks should 
take a nsNSAID with a PPI.  
 
Keywords:  NSAID, nonsteroidal anti-inflammatory drugs, ibuprofen, COX2 inhibitors, 
cyclooxygenase, peptic ulcer disease, ulcer bleeding, omeprazole, misoprostol, gastrointestinal, 
upper gastrointestinal and perforated ulcers. 
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EFFECTS AND PREVENTION OF CHRONIC NSAID USE ON THE STOMACH 
 
INTRODUCTION 
 
 Each year approximately 30 billion over-the-counter (OTC), nonsteroidal anti-
inflammatory (NSAID) tablets are sold1 and 60 million prescriptions are written for 
NSAIDs, of which 3.6 times more are written for elderly patients than for younger 
patients2.  In fact, after the introduction of COX-2 inhibitors in the year 2000, the number 
of prescriptions written for NSAIDs was >111 million at a cost of $4.8 billion1.  
Currently in the United States there are at least 20 types of NSAID’s available by 
prescription and/or OTC and more in other parts of the world2 (Table I). 
 An NSAID is defined as a drug that has “analgesic, anti-inflammatory, and 
antipyretic actions”3.  It is used to treat “acute and chronic pain, including the pain of 
injuries, arthritis, and dysmenorrhea; to reduce inflammation; and to prevent 
complications in serious illness, such as sepsis”3.  This versatility of NSAID’s has led to 
an increased popularity of the drug.  Unfortunately, aspirin and other NSAID’s can injure 
the gastric and duodenal mucosa, leading to considerable morbidity and mortality4.  In 
fact, patients who take NSAID’s have a 4 to 7-fold increased risk of developing a type of 
gastric injury5.  These gastric injuries can range from nausea and dyspepsia to serious 
gastrointestinal (GI) complications such as peptic ulcerations complicated by bleeding or 
perforation1.  The risk of developing a GI complication is not the same for all patients, 
the risk of bleeding increases with the presence of risk factors5 (see Table II).  It has been 
estimated that GI toxicity related to NSAID use in the US population is attributable to 
approximately “3200 to >16,500 deaths annually”6.    Therefore, the prevention of GI 
injury due to NSAID use is an important clinical issue.   
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 The purpose of this review was to determine the current recommendations for the 
prescribing of NSAID’s and the prevention of concurrent GI damage with NSAID use.  
As stated above, the prevalence of aspirin and NSAID use in the United States alone is 
significant and as the population continues to age will become more so in the upcoming 
future, therefore being able to prevent gastric injury is imperative.   
 
BACKGROUND 
History of NSAIDs  
 The first original NSAID was discovered in 1763, called sodium salicylate and 
was used in various impure forms as an antipyretic and as an analgesic7.  Even back then 
there were gastrointestinal side effects associated with the use of acetylsalicylic acid 
(ASA) which in turn led to the evolution over a period of time of over “20 different 
drugs, from six major classes determined by their chemical structures, available for use in 
the United States”7 (Table 1).  Many of these drugs were developed also in hopes to 
increase patient’s compliance with their medication adherence by decreasing the absolute 
number of pills and frequency of which they are taking them each day.  Other purposes 
were to reduce the toxicity of the drug and to increase the anti-inflammatory effect. 
 
Mechanism of Action of NSAID’s 
 The primary effect of NSAID’s is to inhibit cyclooxygenase.  Cyclooxygenase is 
one of several enzymes (COX1, COX2, etc) that make prostaglandins from arachidonic 
acids8.  They play a central role in inflammatory diseases, blood clotting, pain and 
cellular proliferation8.  By inhibiting cyclooxygenase, NSAIDs prevent arachidonic acid 
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from producing prostaglandins which are important mediators in the inflammatory 
process7 (see Figure I).  However, prostaglandins also play a role in the protection of the 
gastric and duodenal mucosal lining from luminal acid-pepsin4.  The extent of the 
cyclooxygenase inhibition varies from NSAID to NSAID which may be why different 
patients react differently to the same medication whether it be the effectiveness of the 
drug or the extent of side effects the drug may have on the patient. 
 Cyclooxygenase is expressed as a least two different enzymes, COX1 and COX2.  
They are 50-60% homologous and are coded on different chromosomes.  COX1 has a 
fairly steady rate of expression in most cells of the body and is stimulated by hormones or 
growth factors.  In contrast, COX2 is usually undetectable in most tissues but is 
expressed in cells only when bacterial polysaccharides, pro-inflammatory cytokines such 
as TNFa or IL-1b, or growth factors induce its expression4.   
 Typically in healthy gastric and duodenal mucosa, COX1 is used to produce its 
mucosal protective prostaglandins.  The mechanism of action in many NSAID’s is to 
block the COX1 and COX2 pathways more or less equally (are non-selective) and 
therefore can cause suppression in the production of the prostaglandin that is protective 
of the gastric mucosa.  This can lead to the injury of the gastric mucosa which can have 
considerable morbidity and mortality secondary to gastric ulcer disease. Other types of 
NSAID’s that selectively inhibit the COX2 pathway have less of an impact on the 
suppression of gastric prostaglandin synthesis and therefore less gastric mucosal injuries 
are incurred4.  Table III lists the selectivity for COX-2 for select NSAIDs.       
 
 
 12 
Mechanism of Action for Cox-2 Inhibitors 
 In contrast with non-selective NSAID’s, COX-2 inhibitors “inhibit prostaglandin 
synthesis by decreasing the activity of the enzyme, cyclooxygenase-2, which results in 
decreased formation of prostaglandin precursors”9.  By inhibiting the COX-2 pathway, 
instead of the COX-1 pathway, COX-2 inhibitors have an advantage by showing a lower 
risk for the development of GI bleeding10.  However, all NSAIDs have some inhibitory 
effects on COX-1 and COX-2 activities, so that none is absolutely selective for COX-211.   
 
Mechanism of Action for Drugs that Treat PUD 
 There are numerous drugs available today in the United States that are used for 
treatment and maintenance therapy of peptic ulcer, treatment of gastroesophageal reflux 
disease, and management of dyspepsia12 (see Table IV).  Of these drugs three classes 
have been studied in the prevention or recurrence of PUD with chronic NSAID or COX-2 
usage.   
 H2 receptor antagonists block the actions of histamine at all H2 receptors (see 
Figure II). However, their chief use is to inhibit gastric acid secretion induced by 
histamine or gastrin being particularly effective against nocturnal acid secretion.  The 
four drugs used in the United States (see Table IV) potently inhibit basal, food-stimulated 
and nocturnal secretion of gastric acid after a single dose13.  All four of these agents have 
been effective in promoting healing of gastric ulcers, though recurrence is common after 
treatment is stopped (60-100% per year)13.   
 Proton pump inhibitors (PPI’s) bind to the proton pump of the parietal cell (see 
Figure II), thereby suppressing secretion of hydrogen ions into the gastric lumen13.  At 
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standard doses, all PPI’s inhibit both basal and stimulated gastric acid secretion more 
than ninety percent.  Since PPI’s arrival on the market, they have proven to be superior 
over H2 antagonists for suppressing acid production and healing peptic ulcers. However, 
a study has shown that ‘long-term PPI therapy, particularly at high doses, is associated 
with an increased risk of hip fracture14”. 
 Prostaglandin E2, produced by the gastric mucosa, inhibits secretion of 
hydrochloric acid and stimulates secretion of mucus and bicarbonate, a cytoprotective 
effect13.  Non-selective NSAID’s inhibit the production of prostaglandins and therefore 
their protectiveness over the gastric mucosa which can lead to peptic ulcers.  Misoprostol 
is a stable analog of prostaglandin E1 and has been approved for the prevention of gastric 
ulcers induced by NSAID’s13.  However, Misoprostol has been shown to cause abortion 
premature birth and birth defects, therefore should be avoided with women who are 
pregnant or are of child-bearing potential15.  Other serious side-effects of Misoprostol are 
hypertension, myocardial infarctions and arrhythmias15, so when considering a gastric 
protective measure for a patient with cardiovascular concerns this drug should be 
avoided.     
 In comparison of the three types of treatments, studies have shown “standard 
doses of H2-receptor antagonists were effective at reducing the risk of endoscopic 
duodenal ulcers (RR=0.36; 95% CI: 0.18-0.74) but not gastric ulcers (RR=0.73; 95% 
CI:0.50-1.09). Both double dose H2RAs and PPIs were effective at reducing the risk of 
endoscopic duodenal and gastric ulcers (RR=0.44; 95% CI: 0.26-0.74 and RR=0.40;95% 
CI;0.32-0.51 respectively for gastric ulcer), and were better tolerated than misoprostol16” 
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Peptic Ulcer Disease 
 Peptic ulcer disease  encompasses both gastric and duodenal ulcers. Ulcers are 
defined as breaks in the mucosal surface >5 mm in size, with depth to the submucosa17.  
Gastric ulcers (GU) tend to appear later in life, with peak incidence around the sixth 
decade17.  Most benign GU’s are located distal to the junction between the antrum and the 
acid secretory mucosa17.  The majority of GU's can be attributed to either H. pylori or 
NSAID-induced mucosal damage with other causes associated with genetic 
predisposition, psychological stress, cigarette smoking and diet.   
 Prostaglandins play an important role in maintaining gastroduodenal mucosal 
integrity and repair.  Therefore, interruption of prostaglandin synthesis which occurs with 
NSAID use can impair mucosal defense and repair, leading to mucosal injury.  Figure III 
demonstrates how systematically administered NSAIDs may lead to mucosal injury.   
 Clinical manifestations of PUD include abdominal pain and epigastric pain with 
about 10% of patients presenting without symptoms1.  It is important to do a thorough 
history and physical exam with patients thought to have PUD.  Abdominal pain is 
common to many GI disorders and therefore has a poor predictive value of the presence 
of GU’s1.  Epigastric pain can be described as a burning or gnawing discomfort or as an 
ill-defined, aching sensation or hunger pain1.  The typical pain pattern associated with 
GU’s is associated with the ingestion of food1.  Nausea and weight loss may also be 
associated with a GU1.  The list of GI and non-GI disorders that can mimic ulceration of 
the stomach is long and includes proximal GI tumors, gastroesophageal reflux (GERD), 
vascular disease, biliary colic, chronic pancreatitis and gastroduodenal Crohn’s disease1.   
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 The extent of ulcer complications may be determined by a description of 
symptoms or an increase in ulcer complications may be indicated by a new onset of 
symptoms or a change in frequency of symptoms.  Ulcer complication can be indicated 
by onset of associated symptoms such as nausea and/or vomiting1.  A penetrating ulcer 
may be described as dyspepsia that has become constant, is no longer relieved by food or 
antacids, or radiates to the back1.  A perforation may be indicated by sudden, severe, 
generalized abdominal pain1.  A patient experiencing gastric outlet obstruction will 
present with pain worsening with meals, nausea and vomiting of undigested food1.  A 
bleeding ulcer will present with tarry stools or coffee ground emesis1.   
 Upon physical exam the most frequent finding is epigastric tenderness in patients 
with GU’s1.  A patient with tachycardia or orthostasis may be dehydrated from vomiting 
or active GI blood loss1.  A severely tender, board-like abdomen suggests a perforation1.   
 GI bleeding is the most common complication observed with PUD1.  It occurs in 
approximately 15% of patients and more often in individuals over 60 years of age1.  The 
higher incidence in the elderly is likely due to their increased NSAID use1.   
 Perforation is the second most common ulcer-related complication.  The 
incidence rate has been reported in as many as 6-7% of PUD patients, with the incidence 
in perforation in the elderly increasing secondary to the increased use of NSAID’s1.   
 Gastric outlet obstruction is the least common complication of PUD with the 
occurrence being approximately 1-2% of patients1.  Obstruction may be secondary to 
ulcer-related inflammation and edema in the peripyloric region which often resolves after 
the ulcer has healed1.  Another possible obstruction occurs secondary to scar formation in 
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the peripyloric area which is resolved with an endoscopic balloon dilation or surgical 
intervention1.   
 Diagnostic studies are often used to establish the presence of an ulcer due to the 
multiple disease processes that can mimic PUD.  Documentation of an ulcer requires 
either a barium study or an endoscopic procedure1. However, for patients who are 
otherwise healthy and less than 45 years of age, empirical therapy is appropriate before 
proceeding with an endoscopic evaluation1.   
 Barium studies of the proximal GI tract are still commonly used as a first test for 
documenting an ulcer1.  Typically a benign GU ulcer will appear as a “discrete crater 
with radiating mucosal folds originating from the ulcer margin”1.  Ulcers greater than 3 
cm or those associated with a mass are often malignant in nature1.  Because “8% of GU’s 
that appear to be benign by barium studies are in fact malignant, a barium study that 
shows a GU most be followed up by endoscopy and biopsy”1. 
 Endoscopy provides the most sensitive and specific approach for examining the 
upper GI tract1.  It allows for direct visualization, photographic documentation of the 
mucosal defect and for biopsy to rule out malignancy or H. pylori1.   Endoscopy also 
helps in identifying lesions too small to be detected by barium studies and to determine 
whether an ulcer is a source of blood loss1.  
 
METHODS 
 An extensive literature review in English was performed searching for articles 
over the past 10 years using the following search terms, but not limited to:  NSAID, 
nonsteroidal anti-inflammatory drugs, ibuprofen, COX2 inhibitors, cyclooxygenase, 
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peptic ulcer disease, ulcer bleeding, omeprazole, misoprostol, gastrointestinal, upper 
gastrointestinal and perforated ulcers.  Articles were rejected if the study was not a 
randomized controlled trial or retrospective cohort trial; included exclusively children; 
lasted less than 21 days; or did not measure review outcomes.  Data sources included 
OVID-Medline, PubMed, UpToDate, Taber’s Cyclopedic Medical Dictionary, Epocrates, 
Minneapolis VA Medical Center Research Library and University of New Mexico Health 
and Sciences Library.    
 
RESULTS 
Five GI Protective Strategies 
 In 2004, the British Medical Journal published a study regarding “The 
Effectiveness of Five Strategies for the Prevention of Gastrointestinal Toxicity Induced by 
Non-Steroidal Anti-Inflammatory Drugs: Systematic Review”7(see Appendix A).  The 
five strategies included “H2 receptor antagonists plus nsNSAIDs, PPI’s plus nsNSAIDs, 
misoprostol plus nsNSAIDs, COX-2 selective NSAIDs and COX-2 specific NSAIDs”18.  
The review looked at only randomized controlled trials that assessed gastroprotective 
strategies versus placebo.  The results when comparing gastroprotective strategies versus 
placebo were as follows:  “no evidence of effectiveness of H2 receptor antagonists; 
proton pump inhibitors may reduce the risk of symptomatic ulcers (relative risk 0.09, 
95% confidence interval 0.02 to 0.47); misoprostol reduces the risk of serious 
gastrointestinal complications (0.57, 0.36 to 0.91) and symptomatic ulcers (0.36, 0.20 to 
0.67); COX-2 selectives reduce the risk of symptomatic ulcers (0.41, 0.26 to 0.65) and 
COX-2 specifics reduce the risk of symptomatic ulcers (0.49, 0.38 to 0.62) and possibly 
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serious gastrointestinal complications (0.55, 0.38 to 0.80)”18.  Overall the review 
concluded that “misoprostol, COX-2 specific and selective NSAIDs, and probably proton 
pump inhibitors significantly reduce the risk of symptomatic ulcers, and misoprostol and 
probably COX-2 specifics significantly reduce the risk of serious gastrointestinal 
complications, but data is low”18.     
 
NSAID VS. COX-2 
 When researching the comparison of NSAIDs to COX-2 selective inhibitors, three 
randomized controlled trials demonstrated the same result:  COX-2 selective inhibitors 
are associated with less significant GI effects than nsNSAIDs alone.  In 2000, JAMA 
published the Celecoxib Long-Term Arthritis Safety Study (CLASS) which set out to 
determine “whether celecoxib, a COX 2-specific inhibitor was associated with a lower 
incidence of significant upper GI toxic effects and other adverse effects compared with 
conventional NSAIDs”19.  Patients were randomly assigned to receive either “celecoxib, 
400mg twice daily (2 to 4 times the maximum rheumatoid arthritis and osteoarthritis 
dosages, respectively), ibuprofen, 800mg three times daily or diclofenac, 75mg twice 
daily”19.  Results from this study showed that for all patients, the “incidence rates of 
upper GI ulcer complications alone and combined with symptomatic ulcers for celecoxib 
vs. NSAIDs were 0.76% vs. 1.45% (P=.09) and 2.08% vs. 3.54% (P=.02) respectively”19.  
Overall the study concluded that celecoxib, at dosages greater than those indicated 
clinically, was associated with “a lower incidence of symptomatic ulcers and ulcer 
complications combined, as well as other clinically important toxic effects, compared 
with NSAIDs at standard dosages”19.  However, the results of this study came under 
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scrutiny.  It was stated that “the CLASS study was not designed to compare the efficacy 
of the drugs, and the choice of dosing regimens was based on an analysis of prescription 
patterns, rather than evidence of similar efficacy”20.  The patient population was not equal 
as well, with their being more patients with osteoarthritis than rheumatoid arthritis and 
more being female19.  Also, the trial did not take into account patients already at risk for 
PUD, therefore naturally leading to a higher rate of PUD despite the medication they 
were given.  In addition, only the first six months of data from this trial was published, 
though the trial ended at 13 months20. Another possibility for inaccurate results was that 
patients were allowed, if needed, to take aspirin, up to 325mg daily.  This trial received 
its funding from Pharmacia, the maker of the drug celecoxib, thereby possibly allowing 
for the industry bias in the published results.   
 In the New England Journal of Medicine in the same year another large trial, 
VIOXX Gastrointestinal Outcomes Research (VIGOR), was published comparing upper 
GI toxicity of NSAIDs vs. COX 2-selective inhibitors, specifically rofecoxib (Vioxx) and 
naproxen, in patients with rheumatoid arthritis21.  Patient’s were randomly assigned to 
receive either 50mg of rofecoxib daily or 500mg of naproxen twice daily21.  Results of 
the VIGOR trial demonstrated “2.1 confirmed gastrointestinal events per 100 patient-
years occurred with rofecoxib, as compared with 4.5 per 100 patient-years with 
naproxen”21.  In conclusion, the study demonstrated “treatment with rofecoxib, a 
selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically 
important upper gastrointestinal events than treatment with naproxen, a non-selective 
inhibitor”21.  However, the VIGOR trial also revealed a link to an increased risk of 
myocardial infarctions with the use of rofecoxib with the rates of myocardial infarctions 
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in the naproxen group being 0.1% and in the rofecoxib group being 0.4%.21  The trial 
attributed this significance to the high rate of myocardial infarctions occurring in the 
population with the highest risk of myocardial infarctions, whom low dose aspirin was 
indicated.  Since this trial was published, rofecoxib and other COX2 selective inhibitors 
were taken off of the market due to the cardiovascular side effects.  This trial received 
funding from Merck and many of the participating authors had ties to the company at 
time of the trial, thereby leading to probable industry bias towards rofecoxib.   
 In 1999 the Lancet published a study titled “Celecoxib versus diclofenac in long-
term management of rheumatoid arthritis: randomized double-blind comparison”22.  
Patients were “randomly assigned celecoxib, 200mg twice daily or diclofenac SR 75mg 
twice daily for 24 weeks”22.  Findings stated that “gastroduodenal ulcers were detected 
endoscopically in 15% of patients treated with diclofenac and in 4% of patients in the 
celecoxib group (P<0.001)”22, thereby leading to the conclusion that celecoxib “had a 
lower frequency of upper gastrointestinal ulceration”22 than diclofenac.  Conversely, this 
study was supported by G D Searle and Co., the company that makes celecoxib.  Though 
their data appears straight forward, some of the data may have had a different outcome if 
patients positive for H. pylori and patients with a history of GI complications were 
excluded from this trial.   
 
COX-2 vs. NSAID + PPI 
 An article was published in the New England Journal of Medicine in 2002 
regarding a study titled “Celecoxib versus Diclofenac and Omeprazole in Reducing the 
Risk of Recurrent Ulcer Bleeding in Patients with Arthritis”23.  In this study patients were 
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randomly assigned to either receive “celecoxib, 200mg twice daily plus omeprazole 
placebo daily or 75mg of extended-release diclofenac twice daily plus 20mg of 
omeprazole daily for six months”23.  “A committee identified 16 cases of recurrent ulcer 
bleeding, 7 in the celecoxib group and 9 in the diclofenac-plus-omeprazole group”23.  
Overall, the “probability of recurrent bleeding was 4. 9% in the celecoxib group and 
6.4% in the diclofenac-plus-omeprazole group, with the difference between the two 
groups not being significant (P=0.60 by the log-rank test)”23.  The study also calculated 
the probability for recurrent bleeding in patients not taking concomitant aspirin as being 
4.5% in the celecoxib group and 5.6% in the combination therapy group23.   The study 
concluded that “the treatment with celecoxib (alone) was as effective as treatment with 
diclofenac plus omeprazole, with respect to the prevention of recurrent bleeding”23.  
However, the study warns that even though the two methods were as effective, the risk of 
recurrent bleeding with either treatment was high, suggesting that neither regimen could 
completely protect patients at high risk from recurrent ulcer complications23.  An 
important note about this study was that two of the co-authors received consulting fees 
from drug companies; One from Novartis the maker of Voltaren XR (diclofenac) and the 
other from Pfizer the current manufacturer of celecoxib.  However, in regards to the 
former author, the study was performed prior to the merger between Pfizer and 
Pharmacia in 2003.  During this study Pharmacia manufactured celecoxib.  In spite of 
this, the article appeared to present its data clearly and fairly and also recognized the 
limitations of the study.   
 Another similar study was published in 2005 in The American Journal of 
Medicine, titled “Celecoxib compared with lansoprazole and naproxen to prevent 
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gastrointestinal ulcer complications”24  For this study patient’s were “randomly assigned 
to treatment with celecoxib 200mg daily alone or naproxen 750mg daily and lansoprazole 
30mg daily for 24 weeks”24.  At 24 weeks “4 patients (3.7%, 95% confidence interval 
(CI) 0.0%-7.3%) in the celecoxib group, compared with 7 patients (6.3%, 95% CI 1.6%-
11.1%) in the naproxen and lansoprazole group, developed recurrent ulcer complications 
(absolute difference -2.6%, 95% CI for the difference -9.1% - 3.7%)”24.  The study 
concluded that in patients with a history of nsNSAID-related complicated peptic ulcers, 
celecoxib alone was statistically as effective as the co-therapy of naproxen and 
lansoprazole in the prevention of recurrent ulcer complications24   As in the previous 
study, it was found the two therapies were as effective in reducing ulcer complication 
recurrence, yet they were still associated with a significant proportion of ulcer 
complication recurrences (4%-6%)24. This was found to occur especially in the 
population of patients 65 years of age and older24.  This study was not funded by a 
pharmaceutical company, though since it was not a placebo-controlled study, there may 
still have been a possible bias.    
 
COX-2 vs. COX-2 plus PPI  
 In 2007, The Lancet published a study titled “Combination of a cyclo-oxygenase-
2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in 
patients at very high risk: a double-blind, randomized trial”25 (see Appendix B).  The 
study defined “very high risk” as patients with a previous history of ulcer bleeding25. 
Patients participating in this study were all given celecoxib 200mg twice daily, then half 
were randomly assigned to receive either 20mg of esomeprazole twice daily or to receive 
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a placebo for 12 months.  Of 21 suspected serious GI events, 12 cases were identified as 
recurrent ulcer bleeding, all being from the celecoxib only group25.  The study stated its 
findings as “combination treatment was more effective then celecoxib alone for 
prevention of ulcer bleeding in patients at high risk”25.  This study appeared to present its 
data clearly, without bias and did well to recognize the limitations of the study itself.  
They noted the design was not able to assess the best possible management for patients 
with high cardiovascular risk and therefore the role of concomitant aspirin in relation to 
the efficacy of COX-2 inhibitors.   Though this study was not sponsored by a 
pharmaceutical company, some of the authors had received grant support from different 
drug companies associated with the study drugs, though it is unclear if it was to aid in this 
research.   
 
nsNSAID plus PPI vs. COX-2 plus PPI 
 In 2006, a study was published in the American Journal of Gastroenterology titled  
“Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and 
COX-2 inhibitors”26 (See Appendix C).  Two similar studies, titled The Verification of 
Esomeprazole for NSAID Ulcers and Symptoms (VENUS) and the Prevention of Latent 
Ulceration treatment Options (PLUTO), were performed at the same time with patients 
requiring daily NSAIDs, including COX-2 inhibitors26.  They were randomly assigned to 
be given either esomeprazole (20 or 40mg) or placebo, daily for 6 months26.  In the 
VENUS study the proportion of “patients who developed ulcers over 6 months was 
20.4% on placebo, 5.3% on esomeprazole 20mg (P<0.001) and 4.7% on esomeprazole 
40mg (P<0.0001)”26.  In the PLUTO study, “the values were 12.3% on placebo, 5.2% 
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with esomeprazole 20mg (P=0.018) and 4.4% with esomeprazole 40mg (P=0.007)”26.  
Overall “significant reductions were observed for users of both non-selective NSAIDs 
and COX-2 inhibitors”26, leading to a conclusion that “for at-risk patients, esomeprazole 
was effective in preventing ulcers in long-term users of NSAIDs, including COX-2 
inhibitors”26  The two studies used similar protocols, except for minor local variations.  
However, some differences noted between the two groups may have led to limitations of 
this study.  One difference was the number of participants in each study.  The VENUS 
study had 844 patients all from the United States and the PLUTO study had 585 patients 
from 11 different countries, including the United States26.  Comparison of the two groups 
may have been skewed due to multiple variables.  Another possible source of a limitation 
could have been that 10% of the VENUS population had a history of ulcers as their sole 
risk versus being >60 years of age, whereas 25% of the PLUTO population had ulcers as 
their sole risk26, possibly leading to the higher percentage of recurrent ulcers in the 
PLUTO group.  It was also noted that AstraZeneca, the manufacturer of esomeprazole, 
provided the research grant and financial assistance for the VENUS and PLUTO studies.  
       
DISCUSSION 
Overall Conclusions and Recommendations 
 Many of the early studies comparing nsNSAIDs to COX-2 inhibitors when COX-
2 inhibitors first appeared on the market found COX-2 inhibitors to be statistically 
superior to nsNSAIDs in preventing PUD.  However, it was determined that many of 
these studies published biased results or were not forth coming in all of the results due to 
the fact the trials were funded by the drug companies of the specific study drug.  In  
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recent years additional studies have been published with higher validity demonstrating 
the combination of an nsNSAID with a PPI is as effective in gastroprotection as a COX-2 
inhibitor alone24 and the combination of a COX-2 inhibitor with a PPI is more effective 
in gastroprotection than a COX-2 inhibitor alone25.  With the recent removal from the 
market of many COX-2 inhibitors because of increased cardiovascular risks, many 
patients and practitioners have valid concerns about taking and prescribing COX-2 
inhibitors, though still are concerned with prevention of PUD in patients in need of 
chronic NSAID use.  Consequently, over the past few years recommendations have been 
put forth to aide in this decision making process (see Table V).        
 An article titled “The relative efficacies of gastroprotective strategies in chronic 
users of nonsteroidal anti-inflammatory drugs” published in Gastroenterology (2008) 
proposed recommendations as follows:  In high-risk patients requiring chronic NSAID 
use, a COX-2 inhibitor plus a PPI is suggested27.  For those patients whom a COX-2 
inhibitor is contraindicated because of either cardiac disease or the cost of both 
medications is prohibitive, either the combination of a nsNSAID plus misoprostol plus a 
PPI or the combination of nsNSAID plus a PPI or low dose misoprostol is their 
recommendation27.   
 In 2004, Alimentary Pharmacology and Therapeutics, published an article titiled 
“Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-
oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic 
anti-inflammatory therapy”28 (See Appendix E).  These guidelines are as follows:  “the 
use of an NSAID alone is appropriate for those aged <65 years, and the use of an NSAID 
plus proton pump inhibitor or cyclo-oxygenase-2-selective inhibitor plus proton pump 
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inhibitor is  not appropriate”28.  “For patients aged >65 and at low risk, an NSAID or 
cyclo-oxygenase-2-selective inhibitor alone was rated as ‘uncertain’28.”  For patients with 
a previous GI event or who concurrently received aspirin, an NSAID alone was rated as  
not appropriate28, and either “a cyclo-oxygenase-2-selective inhibitor or an NSAID + 
proton pump inhibitor was rated as ‘appropriate’”28.  “Finally, for patients with a 
previous gastrointestinal event and on aspirin, an NSAID or cyclo-oxygenase-2-selective 
inhibitor in conjunction with a proton pump inhibitor was rated as ‘appropriate’”28.   
 
LIMITATIONS OF STUDY 
 There are many studies that have looked at the efficacy of NSAID’s and COX-2 
inhibitors whether alone or with combination therapy of a PPI.  However, chronic PPI 
usage has been linked to complications such as “community acquired pneumonia, C-dif 
associated diarrhea and hip fractures”27.  There currently is no research detailing the 
risk/benefit ratio of chronic PPI usage29.  To tie into this research it may be of value to 
study H2 receptor antagonists vs. PPI’s as there is very little research and no recent 
research comparing the two in their efficacy to decrease PUD while taking NSAIDs.   
 The research provided does not take into account patient compliance associated 
with the number of pills they have to take29.  It may be beneficial to assess compliance in 
patients by treating with one combination NSAID/PPI pill versus separately prescribed 
mediations.   
         
 
 
 27 
CONCLUSIONS 
 NSAIDs are among the most widely used drugs and their usage will continue to 
increase as our population continues to age.  Therefore, it is imperative to be aware of the 
side effects these drugs can have on a person and how to prevent them from occurring.  
The recommendations presented above are a step in this direction.   Of course these are 
only guidelines and are here to assist in the process of balancing the risks and benefits, 
and the cost of medications28.  As always “regulatory advice and good clinical practice 
are to use anti-inflammatory drugs at the lowest effective dose and for the shortest 
possible time”30. 
 
 
 
 
Table I 
The nonsteroidal anti-inflammatory drugs  
NSAID Trade name Usual dose 
Carboxylic acids 
Aspirin (acetylsalicylic 
acid) Multiple 2.4-6 g/24h in 4-5 divided doses 
Buffered aspirin Multiple Same 
Enteric-coated salicylates Multiple Same 
Salsalate Disalcid 1.5-3.0 g/24h BID 
Diflunisal Dolobid 0.5-1.5 g/24h BID 
Choline magnesium 
trisalicylate Trilisate 1.5-3 g/24h BID-TID 
Proprionic acids 
Ibuprofen Motrin, Rufen, OTC OTC:200-400 mg QID; Rx: 400-800 mg; max 3200 mg/24h 
Naproxen; Enteric Naprosyn, Anaprox, OTC: Alleve 250, 375, 500 mg BID; 225 mg BID 
Fenoprofen Nalfon 300-600 mg QID 
Ketoprofen Orudis; Oruvail 75 mg TID; q day 
Flurbiprofen Ansaid 100 mg BID-TID 
Oxaprozin Daypro 600 mg; 2 tabs per day 
Acetic acid derivatives 
Indomethacin Indocin, Indocin SR 25, 50 mg TID-QID; SR:75 mg BID; rarely >150 mg/24h 
Tolmetin Tolectin 400, 600, 800 mg; 800 to 2400 mg/24h 
Sulindac Clinoril 150, 200 mg BID; some increase to TID 
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Diclofenac (plus 
misoprostol) 
Voltaren; Cataflam; 
(Arthrotec) 50, 75 mg BID (50 mg BID) 
Etodolac Lodine 200, 300 mg BID-QID; max:1200 mg/24h 
Fenamates 
Meclofenamate Meclomen 50-100 mg TID-QID 
Mefenamic acid Ponstel 250 mg QID 
Enolic acids 
Piroxicam Feldene 10, 20 mg q day 
Phenylbutazone Butazolidin 100 mg TID up to 600 mg/24h 
Napthylkanones 
Nabumetone Relafen 500 mg BID up to 1500 mg/24h 
Selective COX-2 inhibitors 
Celecoxib Celebrex 100, 200 mg a day 
 
 
 
 
 
 
 
 
 
 
 
Table II 
Factors related to increased risk of NSAID-induced GI complications  
Risk factor Relative risk 95% CI 
Overall 2.74 2.54-2.97 
Age (>60) 5.52 4.63-6.60 
Prior GI event 4.76 4.05-5.59 
High dosage (>2 X normal) 10.1 4.6-22.0 
Concurrent corticosteroids 4.4 2.0-9.7 
Concurrent anticoagulants 12.7 6.3-25.7 
Reproduced with permission from the American College of Gastroenterology. Lanza, FL. 
A guideline for the treatment and prevention of NSAID-induced ulcers. Am J 
Gastroenterol 1998; 93:2037.  
 
 
 
 
 
 
 
 
 
 
 
 29 
Table III 
Selected NSAIDs and other analgesics: selectivity for cyclooxygenase-2 and potency 
in inhibiting gastric COX activity  
   COX-2 selectivity*  Gastric IC   
Salicylates  
Aspirin (acetylsalicylic acid)  0.3 0.03 
Salsalate (salicylsalicylic 
acid)  2.8 >100 
Acetaminophen  4.0 >100 
NSAIDs  
Ketoprofen  0.1 0.08 
Ibuprofen  0.6 0.70 
Indomethacin  0.7 0.85 
Naproxen  1.0 0.52 
Piroxicam  1.3 0.87 
Ketoralac  1.5 0.33 
Nabumetone  1.6 0.48 
Etodolac  7.9 3.20 
Celecoxib  9.2 11.14 
Mefenamic acid  12.1 0.70 
Nimesulide (not available in 
US)  58.3 1.49 
* In whole blood assays in man. A number 1 indicates COX non-selectivity while 
numbers much >1 indicate COX-2 selectivity. Values for nabumetone are for its active 
metabolite, 6-MNA. Value for salsalate is a minimum, since this drug did not inhibit 
COX-2 in whole blood at any concentration tested. 
Concentration of drug in µM that inhibits human gastric mucosal COX activity by 50% 
and thus gastric mucosal PG production by 50%. The lower the IC50, the more potent the 
inhibition of gastric COX activity for a given drug. 
Adapted from Cryer, B, et al. Am J Med 1998; 104:413.  
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Table IV 
 
Drugs Used In The Treatment of Peptic Ulcer Disease 
Drug Type/Mechanism Examples Dose 
Acid-suppressing drugs   
 
Antacids Mylanta, Maalox, Tums, 
Gaviscon 
100-140 meq/L 1 and 3 h after 
meals and hs 
 H2 receptor antagonists Cimetidine 400 mg bid 
 Ranitidine 300 mg hs 
 Famotidine 40 mg hs 
 Nizatidine 300 mg hs 
 Proton pump inhibitors Omeprazole 20 mg/d 
 Lansoprazole 30 mg/d 
 Rabeprazole 20 mg/d 
 Pantoprazole 40 mg/d 
 Esomeprazole 20 mg/d 
Mucosal protective agents   
 Sucralfate Sucralfate 1 g qid 
 Prostaglandin analogue Misoprostol 200 µg qid 
 
Bismuth-containing 
compounds 
Bismuth subsalicylate (BSS) 
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Table V 
Guide to NSAID Therapy 
 No/Low NSAID GI Risk NSAID GI Risk 
No CV risk (no 
aspirin) 
Traditional NSAID Coxib or 
Traditional NSAID + PPI 
  Consider non-NSAID therapy 
CV risk 
(consider 
aspirin) 
Traditional NSAID + PPI if GI 
risk warrants gastroprotection 
A gastroprotective agent must be added 
if a traditional NSAID is prescribed 
 Consider non-NSAID therapy Consider non-NSAID therapy 
Note: NSAID, nonsteroidal anti-inflammatory drug; GI, gastrointestinal; CV, 
cardiovascular; PPI, proton pump inhibitor. 
Source: Adapted from AM Fendrick: Am J Manag Care 10:740, 2004. 
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Figure I 
Prostaglandin and thromboxane synthesis 
 
. 
Schematic representation of the steps involved in synthesis of prostaglandin E2 (PGE2) 
and prostacyclin (PGI2). Characteristics and distribution of the cyclooxygenase (COX) 
enzymes 1 and 2 are also shown. TXA2, thromboxane A2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
Figure II 
 
Actions of antiulcer medications  
 
H2 receptor antagonists (H2RAs) inhibit acid secretion by blocking histamine H2 
receptors on the parietal cell. The proton pump inhibitors (eg, omeprazole, lansoprazole, 
and pantoprazole) effectively block acid secretion by irreversibly binding to and 
inhibiting the hydrogen- potassium ATPase pump that resides on the luminal surface of 
the parietal cell membrane. The mechanism involved in antacid healing of peptic ulcers 
may include neutralizing gastric acid, but probably also includes a number of other 
factors. 
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Figure III 
Mechanisms by which NSAIDs may induce mucosal injury. 
 
(Adapted from J Scheiman et al: J Clin Outcomes Management 3:23, 1996.) 
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